Table 3.
Multivariate analysis of variables associated with the incidence of the primary endpoint
| Meeting primary endpoint(N = 49) | Not meeting primary endpoint(N = 53) | Univariate analysis |
Multivariate analysis |
|||
|---|---|---|---|---|---|---|
| OR (95% CIs) | p value | OR (95% CIs) | p value | |||
| Age, years, mean (SD) | 60.0 (15.3) | 66.7 (13.1) | 0.97 (0.94–0.99) | 0.02 | * | |
| Male sex, n (%) | 37 (75.5) | 42 (79.2) | 0.81 (0.32–2.05) | 0.81 | ** | |
| Mechanical ventilation, n (%) | 29 (59.2) | 42 (79.2) | 0.38 (0.16–0.91) | 0.03 | * | |
| CCI, mean (SD) | 2.19 (1.75) | 3.12 (2.22) | 0.79 (0.63–0.98) | 0.03 | 0.77 (0.62–0.96) | 0.02 |
| PSI, mean (SD) | 77.3 (31.9) | 92.9 (29.7) | 0.98 (0.97–0.99) | 0.02 | * | |
| APACHE II score, mean (SD) | 11.1 (12.6) | 10.4 (4.4) | 1.00 (0.96–1.05) | 0.75 | ** | |
| SOFA score, mean (SD) | 4.46 (2.29) | 4.62 (2.14) | 0.96 (0.81–1.15) | 0.69 | ** | |
| PaO2/FiO2, mm Hg, mean (SD) | 175.1 (117.9) | 136.8 (61.7) | 1.00 (0.99–1.01) | 0.06 | * | |
| Absolute neutrophil count,/mm3, mean (SD) | 8,212.7 (4,937.8) | 8,287.3 (5,348.2) | 1.00 (0.99–1.00) | 0.85 | ** | |
| Absolute lymphocyte count,/mm3, mean (SD) | 949.7 (707.6) | 767.0 (577.9) | 1.00 (0.99–1.00) | 0.24 | ** | |
| Platelet count, x103/mm3, mean (SD) | 242.0 (83.7) | 275.2 (120.7) | 1.00 (0.99–1.00) | 0.16 | ** | |
| AST, U/L, mean (SD) | 51.9 (32.7) | 48.1 (34.4) | 1.00 (0.99–1.02) | 0.60 | ** | |
| ALT, U/L, mean (SD) | 52.7 (40.3) | 47.8 (41.7) | 1.00 (0.99–1.01) | 0.58 | ** | |
| Ferritin, ng/mL, mean (SD) | 1,635.5 (1,643.1) | 2,416.6 (3,103.9) | 1.00 (0.99–1.00) | 0.14 | ** | |
| Anakinra treatment, n (%) | 35 (70.0) | 25 (48.1) | 2.80 (1.23–6.37) | 0.02 | 3.11 (1.29–7.73) | 0.01 |
| Azithromycin treatment, n (%) | 32 (65.3) | 24 (45.3) | 2.10 (0.94–4.68) | 0.07 | * | |
| Hydroxychloroquine treatment, n (%) | 5 (27.8) | 13 (72.2) | 0.35 (0.11–1.07) | 0.07 | * | |
| Glycopeptide treatment, n (%) | 17 (34.7) | 11 (20.8) | 2.02 (0.83–4.92) | 0.13 | * | |
| Dexamethasone treatment, n (%) | 28 (57.1) | 37 (69.8) | 0.58 (0.26–1.30) | 0.19 | ** | |
| Remdesivir treatment, n (%) | 14 (28.6) | 17 (32.1) | 0.85 (0.36–1.98) | 0.70 | ** | |
APACHE, Acute Physiology and Chronic Health Evaluation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CCI, Charlson's Comorbidity Index; CI, confidence interval; OR, odds ratio; PSI, Pneumonia Severity Index; SOFA, Sequential Organ Failure Assessment; SD, standard deviation. * Variables were included in the equation of the multivariate analysis but they were excluded after 2 steps of analysis. ** Variables not included in the equation.